1. Introduction
===============

The global dissemination of human immunodeficiency virus (HIV) and the fatal clinical results of acquired immunodeficiency syndrome (AIDS) urge scientists and physicians to discover the most potent prophylactic and therapeutic vaccines to combat this deadliest scourge of human society. Live recombinant microorganisms have been used as vectors to develop vaccines for eliciting broad array of immune responses against HIV/AIDS. Antigens of HIV can be brought into live and replication competent or incompetent microorganisms by molecular technologies. Appropriate expression of such antigens can be achieved under suitable conditions. When these recombinant vaccines are introduced to mammalian host, multiple immune responses, especially cytotoxic T lymphocytes (CTLs) activity will be elicited against the products of HIV genes carried by the vectors. A number of live viral vectors including poxvirus ([@bib15]), alphavirus ([@bib16]), adenovirus ([@bib23]), adeno-associated virus ([@bib22]), rabies virus ([@bib21]), measles virus ([@bib12]), and vesicular stomatitis virus ([@bib4]) have been used as potential vectors for the development of HIV vaccines. Early-phase clinical trials of some of these viral vector vaccines have performed in humans. In addition, recombinant bacterial vectors, such as *Listeria monocytogenes* ([@bib18]), *Shigella* ([@bib27]), *Mycobacterium bovis* BCG ([@bib9]), and *Salmonella* ([@bib11]) have also been investigated as potential vectors for the delivery of HIV antigens. Since bacterial live vectors can be produced with less cost and stored via lyophilization, they offer many advantages over viral vectors.

Recombinant *Salmonella enterica serovar* Typhi holds a prominent position among bacterial live vectors. Genetic backgrounds of this bacterium and types of virulence mutations have been well characterized. Recombinant *Salmonella* Typhi vaccines are quite easy to massively produce and store, which make these vaccinations economically more feasible and accessible. Recombinant *S*. Typhi has been used as oral typhoid vaccines and as live vector to deliver heterologous antigens that can stimulate mucosal, humoral, and cellular immune responses after immunizing animals via mucosal surfaces ([@bib10]). Foreign antigens can be stably expressed in the bacteria either from its chromosome harboring the antigen gene or from a plasmid carrying the gene ([@bib20]). We have previously constructed a *S. enterica serovar* Typhi strain carrying the nucleocapsid (N) gene of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) integrated into the bacterial chromosome, which could elicit efficiently immune responses in vaccinated mice ([@bib13]).

In this study, we generated a new recombinant *S.* Typhi vaccine candidate *pil*S^−^ *pil*T^−^Gag^+^ (pVAX1-gp120) by a two-step genetic construction process. This vaccine strain harbors the *gag* gene of HIV-1 integrated into the bacterial chromosome and the *gp120* gene of HIV-1 carried by a eukaryotic plasmid. Immune responses against the two major antigens of HIV-1 were investigated after mucosal immunization of mice with this newly developed vaccine strain. Potential use of this recombinant *S*. Typhi strain as a promising vaccine against HIV/AIDS was also discussed.

2. Materials and methods {#sec1}
========================

2.1. Plasmids, *Salmonella* strains and culture conditions
----------------------------------------------------------

Plasmid pNL4-3 containing the full-length HIV-1 proviral sequence was obtained from NIH AIDS Research & Reference Reagent Program. Plasmid pBluescript II SK (+) was used as the basis for the construction of shift plasmid. Plasmid pVAX-1 was used to express HIV-1 gp120 protein. Plasmid pDNR-LIB was the provider of the Cm^R^ (Chloramphenicol resistance) gene. Plasmid pCMV-Tag 2B was used to construct Gag and gp120 expression plasmids which were applied in the establishment of stable CT26 cell lines constitutively expressing Gag or gp120 antigens.

The parental *S*. Typhi strain J341 was taken from laboratory stock (College of Medicine, Wuhan University, Wuhan, China). The cell culture conditions of all the *Salmonella* strains reported in this paper are listed in [Table 1](#tbl1){ref-type="table"} .Table 1Recombinant *Salmonella* strains constructed and used in this studyStrainsDescriptionsCulture conditions[a](#tbl1fn1){ref-type="table-fn"}*S*. Typhi J341*S*. Typhi wild type Ty2 Vi^−^LB*S*. Typhi ST011*S*. Typhi *pil*S^−^*pil*T^−^(pVAX1)LB Km^R^ Cm^R^*S*. Typhi ST012*S*. Typhi *pil*S^−^*pil*T^−^(pVAX1-gp120)LB Km^R^ Cm^R^*S*. Typhi ST013*S*. Typhi *pil*S^−^*pil*T^−^Gag^+^(pVAX1)LB Km^R^ Cm^R^*S*. Typhi ST014S. Typhi *pil*S^−^*pil*T Gag^+^(pVAX1-gp120)LB Km^R^ Cm^R^[^2]

2.2. Construction of shift plasmid pBRGagCmU
--------------------------------------------

The most important approach used in the construction of our recombinant vaccine is homologous recombination. First, we constructed a new shift plasmid pBRCmU, which can shift a heterologous gene from the plasmid to the chromosome of *S*. Typhi J341 strain. In brief, *pil*R gene from the genome of *S*. Typhi J341 strain was PCR amplified with primers 5′-AGTGGTACCTTGCATGAGTCCTTTATACCG-3′ and 5′-TACGGGCCCTCCAGTTCGACAGGGACCACCTGGT-3′. The PCR product was then inserted into plasmid pBluescript II SK (+) at the KpnI and ApaI sites as the left arm of shift plasmid. *pil*U gene from the genome of *S*. Typhi J341 strain was PCR amplified with primers 5′-ATACCGCGGGCAAACGGGGGCTCAATGACAGTCT-3′ and 5′-TTAGAGCTCACCCCCATCCAGCCTACCAGGGCAC-3′. The PCR product was then inserted into plasmid pBluescript II SK (+) at the SacII and SacI sites as the right arm of shift plasmid. This new plasmid was named pBRU. The Cm^R^ (Chloramphenicol resistance) gene from plasmid pDNR-LIB was amplified by PCR with primers 5′-GGCTCTAGAAGGAAGCTAAAATGGAGAA-3′ and 5′-AAACCGCGGAAATTACGCCCCGCCCTGCC-3′ and then inserted into plasmid pBRU at the XbaI and SacII sites to generate shift plasmid pBRCmU.

The *gag* gene of HIV-1 was amplified from plasmid pNL4-3 by PCR with primers 5′-ATACTCGAGGAGATGGGTGCGAGAGCGT-3′ and 5′-GGCGAATTCATCTTTATTGTGACGA-3′ and then inserted into shift plasmid pBRCmU at XhoI and EcoRI sites to yield shift plasmid pBRGagCmU ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Schematic diagram of the construction of recombinant *Salmonella enterica serovar* Typhi strain *S*. Typhi *pil*S^−^*pil*T^−^Gag^+^. Plasmid pBRGagCmU (upper part) containing the gag gene of HIV-1 and the Cm^R^ gene flanked by the *pli*R and *pli*U genes of *S*. *enterica serovar* Typhi was transformed into *S. enterica serovar* Typhi J341 (middle part). The HIV-1 gag gene and Cm^R^ gene carried by the plasmid were then integrated into the *pil*R and *pil*U loci of *S. enterica serovar* Typhi J341 chromosome through homologous recombination chromosomal segments to generate recombinant *S. enterica serovar* Typhi strain *S.* Typhi *pil*S^−^*pil*T^−^Gag^+^ (bottom part). In this recombinant strain the expression of HIV-1 gag gene was under the control of the pilus promoter of the bacterium.

2.3. Construction of recombinant *S*. *enterica serovar* Typhi strain *S*. Typhi *pil*S^−^*pil*T^−^Gag^+^ strain stably expressing Gag antigen of HIV-1
-------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmid pBRGagCmU was transformed into *S*. *enterica serovar* Typhi J341 via the *S*. *enterica serovar* Typhimurium modifying strain J357 and with selection for Amp^R^ and Cm^R^ colonies. Individual clones were selected and grown in 5 ml LB media without antibiotic selection at 42 °C for 24 h. Then 0.05-ml aliquots were transferred into 5 ml fresh medium. After three to four transfers, aliquots were plated onto LB media containing Cm and the grown-up colonies that had already lost transformed plasmid pBRGagCmU were confirmed by checking for Amp sensitivity. Finally, the recombinant *S*. *enterica serovar* Typhi *pilS* ^−^ *pilT* ^−^Gag^+^ strain (ST014), in which the *gag* gene was integrated into the bacterial genome, were isolated from the above colonies by screening for both Cm resistance and Amp sensitivity. The integration of the *gag* gene was examined by PCR amplification using primers adjacent to the inserted fragment.

2.4. Western blot assay for Gag expression
------------------------------------------

The cultured recombinant *S*. Typhi strain *pil*S^−^ *pil*T^−^Gag^+^ was sonicated on ice and the cell lysate was electrophoresed on 12% SDS polyacrylamide gels and transferred overnight to a cellulose nitrate membrane. After transfer, the membrane was blocked in 5% skim milk powder/PBS containing 0.1% Tween (PBS-T) for overnight with shaking at 60 rpm. Then the membrane was washed three times with PBS-T for 10 min per wash and incubated for 1 h at RT with 1:1000 diluted mouse anti-P24 monoclonal antibodies. The cellulose nitrate membrane was washed three times with PBS-T and incubated with horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (1:2000 diluted, Sigma--Aldrich, Germany) in PBS-T for 1 h at RT. The membrane was incubated with chromogen and exposed to X-ray film for 30 s and 1 min.

2.5. Construction of plasmid pVAX1-gp12
---------------------------------------

The *gp120* gene of HIV-1 was amplified from plasmid pNL4-3 using primers 5′-TCGGGATCCGTGGCAATGAGAGTGAAG-3′ and 5′-GCTGAATCCTCATCCTATTCCCACTGC-3′. The PCR product was then inserted into plasmid pVAX1 at the BamHI and EcoRI sites to generate a eukaryotic expression plasmid pVAX1-gp120.

2.6. Western blot assay for gp120 expression
--------------------------------------------

The eukaryotic expression plasmid pVAX1-gp120 was transfected into 293T cells according to the standard cell transfection procedure. Transfected cells were harvested in 48 h and sonicated on ice subsequently. After centrifugation, the supernatant was used for western blot assay. Serum from an HIV-1 positive patient was used as the source of primary antibody (1:1000 diluted). The secondary antibody was horseradish peroxidase (HRP)-labeled goat anti-human IgG (1:2000 diluted, Sigma--Aldrich, Germany).

2.7. Construction of *S*. *enterica serovar* Typhi vaccine candidate strain *S*. Typhi *pil*S^−^*pil*T^−^Gag^+^ (pVAX1-gp120)
-----------------------------------------------------------------------------------------------------------------------------

Plasmid pVAX1-gp120 was modified by J357 and transformed into the recombinant strain *S*. Typhi *pil*S^−^ *pil*T^−^Gag^+^ to yield the strain *S*. Typhi *pil*S^−^ *pil*T^−^Gag^+^(pVAX1-gp120) (also named ST014) as the vaccine candidate strain.

2.8. Construction of recombinant *Salmonella* control strains
-------------------------------------------------------------

By using similar approaches, three different control recombinant strains were also constructed. In strain *S*. Typhi *pil*S^−^ *pil*T^−^(pVAX1) (ST011), the shift plasmid pBRCmU carrying only the Cm^R^ gene was integrated into the bacterium J341 genome and plasmid pVAX1 was transformed into the bacterium subsequently. In strain *S*. Typhi *pil*S^−^ *pil*T^−^(pVAX1-gp120) (ST012), the shift plasmid pBRCmU carrying only the Cm^R^ gene was integrated into the bacterium J341 genome and plasmid pVAX1-gp120 instead of pVAX1 was transformed into J341 compared to ST011. In strain *S*. Typhi *pil*S^−^ *pil*T^−^Gag^+^ (pVAX1) (ST013), the shift plasmid pBRGagCmU was integrated into the bacterium J341 genome and plasmid pVAX1 was transformed into J341 ([Table 1](#tbl1){ref-type="table"}).

2.9. Establishment of stable CT26 cell lines constitutively expressing Gag or gp120 antigens
--------------------------------------------------------------------------------------------

The *gag* gene and *gp120* gene of HIV-1 were amplified by PCR from plasmid pNL4-3 using primers for Gag: 5′-GCAGGATCCATGGGTGCGAGAGCGTCGGT-3′ and 5′-ACGGAATTCTTATTGTGACGAGGGGTCGC-3′, and primers for gp120: 5′-TCGGGATCCGTGGCAATGAGAGTGAAG-3′ and 5′-GCTGAATCCTCATCCTATTCCCACTGC-3′. PCR products were then inserted, respectively at the BamHI and EcoRI sites of plasmid pCMV-Tag2B to generate the eukaryotic expression plasmids pCMV-Tag2B-Gag and pCMV-Tag2B-gp120. These two plasmids were then transfected into mouse CT26 cells. After G418 selection for 30 days, the antigen constitutively expressing cells were checked by RT-PCR and stored as targeted cells for cytotoxicity assay.

2.10. Immune responses of recombinant *S*. Typhi in mice
--------------------------------------------------------

### 2.10.1. Mice immunization

Female BALB/c mice aged 6--8 weeks were randomly divided into five groups with five mice in each group. Group 1 was immunized with *S*. Typhi ST011, group 2 with *S*. Typhi ST012, group 3 with *S*. Typhi ST013, group 4 with *S*. Typhi ST014, and group 5 was PBS control group. Mice were immunized intranasally with 10^9^ CFU of bacteria in 10 μl of PBS. The booster immunization with 10^9^ CFU in 10 μl PBS was also given intranasally 15 days after first immunization.

### 2.10.2. ELISA for mouse serum anti-gp120 IgG and anti-Gag IgG

Immulon II microtiter plates coated with purified HIV-1 Env protein or purified recombinant p24 protein (Dynatech Laboratories, USA) were used in ELISA for detection of mouse serum anti-gp120 IgG and anti-Gag IgG. Plates were washed five times with PBS-T, blocked with 3% BSA in PBS-T at room temperature for 1 h prior to the addition of mouse sera. Sera were subjected for titer determination in eight twofold dilutions staring at 1:100 up to 1:12800. Antibodies bound to the immobilized protein antigens were detected using horseradish peroxidase-labeled goat anti-mouse IgG diluted 1:5000 in PBS-T containing 1% BSA and substrate solution containing *o*-phenylenediamine (1 mg/ml) and H~2~O~2~ (0.03%) in 0.1 M citrate-phosphate buffer. The reaction was stopped with 2 mM H~2~SO~4~. The absorbance was measured on a model 3550 Microplate Reader (Bio-Rad Laboratories, USA) at 450 nm. Test and control sera were run in duplicate.

### 2.10.3. ELISA for mouse mucosal anti-gp120 IgA

To detect the mucosal secreted IgA (S-IgA) level stimulated by the vaccine candidate, we harvested fecal, vaginal, and saliva samples from immunized mice. Immulon II microtiter plates coated with purified HIV-1 Env protein (Dynatech Laboratories, USA) were used in ELISA for the detection of anti-gp120 IgA in mouse samples. These mucosal samples were mixed with an equal volume of PBS and eight twofold dilutions of their supernatants were used for ELISA. Samples were added into microtiter plates at 100 μl per well and incubated at 37 °C for 1 h. Horseradish peroxidase-conjugated goat anti-mouse IgA antibodies were added at a 1:5000 dilution in PBS-T containing 1% BSA for incubation at 37 °C for 1 h. Test and control groups were run in duplicates. So the S-IgAs we detected were mucosal IgA, not plasma IgA.

### 2.10.4. Enumeration of HIV-1 Gag-specific and gp120-specific T cell cytotoxicity by Promega LDH release assay

Splenocytes from immunized BALB/c mice were suspended in complete RPMI-1640 with 10% FCS and analyzed for cytotoxic activity. Serial twofold dilutions of mice splenocytes as expanded effector cells (7.8 × 10^2^ to 2 × 10^5^  cells/wells) were incubated, respectively with target CT26 cells (2 × 10^4^  cells/wells) that stably expressed Gag protein or target CT26 cells (2 × 10^4^  cells/wells) that stably expressed gp120 protein. Cultures were centrifuged at 250 ×  *g* for 4 min and incubated for 4 h at 37 °C in the presence of 5% CO~2~. Fifty microliters of the supernatant per well were then transferred to enzymatic assay plates, and lysis was determined by measuring released lactate dehydrogenase (LDH) by using the Cytotox 96 assay kit (Promega Corp., Madison, WI, USA). The absorbance values from supernatants were recorded at 490 nm on a model 3550 Microplate Reader (Bio-Rad Laboratories, USA). Cultures were tested in triplicate wells. The percentage of cytotoxicity was calculated as follows: (experimental − effector spontaneous − target spontaneous)/(target maximum − target spontaneous) × 100, where spontaneous release is the counts released by target cells in the absence of effector cells and maximal release is the counts released in the presence of lysis solution.

2.11. Statistical analysis
--------------------------

Data were expressed mean ± standard deviation (S.D.) and statistical analyses between groups were performed by one-way analysis of variance (ANOVA) and *q* test using the SPSS 10.0 software. Statistical significance was established at a value of *P*  \< 0.05.

3. Results
==========

3.1. Recombinant *Salmonella* strains harboring the *gag* gene integrated into the bacterial chromosome and the *gp120* gene carried by a plasmid are generated
---------------------------------------------------------------------------------------------------------------------------------------------------------------

To generate the vaccine candidate recombinant *Salmonella* strain *S*. Typhi *pil*S^−^ *pil*T^−^Gag^+^(pVAX1-gp120) (ST014), plasmid pBRGagCmU carrying the *gag* gene of HIV-1 and the antibiotic gene Cm^R^ flanked by the sequences of *Salmonella pil*R and *pil*U genes was initially transformed into *S*. *enterica serovar* Typhi J341. Recombination occurred between the plasmid DNA and *Salmonella* chromosome DNA through homologous recombination within *pil*R and *pil*U genes. The *gag* gene of HIV-1 and Cm^R^ gene were inserted into the chromosome in place of the *pil*S and *pil*T genes of *Salmonella* to generate recombinant strain *S*. Typhi *pil*S^−^ *pil*T^−^Gag^+^ ([Fig. 1](#fig1){ref-type="fig"}). Plasmid pVAX1-gp120 carrying the gp120 gene of HIV-1 was transformed into *pil*S^−^ *pil*T^−^Gag^+^ to yield strain *S*. Typhi *pil*S^−^ *pil*T^−^Gag^+^ (pVAX1-gp120) (named ST014). By using similar approaches, three different control recombinant strains ST011, ST012, and ST013 were also constructed as described in Section [2](#sec1){ref-type="sec"} and listed in [Table 1](#tbl1){ref-type="table"}.

3.2. The *gag* gene and *gp120* gene of HIV-1 are expressed in recombinant *Salmonella* vaccine strains
-------------------------------------------------------------------------------------------------------

The expression of HIV-1 *gag* gene is under the control of pilus promoter of the *Salmonella* chromosome and the expression of HIV-1 *gp120* gene is under the control of P~[CMV]{.smallcaps}~ promoter of plasmid pVAX1 in the vaccine strain ST014. The existing of the foreign genes in recombinant *Salmonella* strains were confirmed by PCR amplification using specific primers for *gp120* ([Fig. 2](#fig2){ref-type="fig"}A), *gag* ([Fig. 2](#fig2){ref-type="fig"}B), and Cm^R^ ([Fig. 2](#fig2){ref-type="fig"}C), respectively. PCR results showed that the *gp120* gene was present in strain ST012 ([Fig. 2](#fig2){ref-type="fig"}A, lane2) and ST014 ([Fig. 2](#fig2){ref-type="fig"}A, lane 4), but not in strain ST011 ([Fig. 2](#fig2){ref-type="fig"}A, lane 1) and ST013 ([Fig. 2](#fig2){ref-type="fig"}A, lane 3). The *gag* gene was detected in strain ST013 ([Fig. 2](#fig2){ref-type="fig"}B, lane 3) and ST014 ([Fig. 2](#fig2){ref-type="fig"}B, lane 4), but not in strain ST011 ([Fig. 2](#fig2){ref-type="fig"}B, lane 1) and ST012 ([Fig. 2](#fig2){ref-type="fig"}B, lane 2). The Cm^R^ gene was detected in all four recombinant *Salmonella* strains ([Fig. 2](#fig2){ref-type="fig"}C, lanes 1--4).Fig. 2Determination of foreign genes in bacterium by PCR analysis. The existing of the foreign genes, gp120 ([Fig. 2](#fig2){ref-type="fig"}A), gag ([Fig. 2](#fig2){ref-type="fig"}B), and Cm^R^ ([Fig. 2](#fig2){ref-type="fig"}C), in recombinant *Salmonella* strains, ST011 (lane 1), ST012 (lane 2), ST013 (lane 3), and ST014 (lane 4), were determined by PCR amplification using specific primers to each genes, respectively. M, DNA molecular markers DL2000.

The status of gp120 protein and Gag protein expression was examined by Western blot analyses using antibody specific to gp120 protein ([Fig. 3](#fig3){ref-type="fig"}A) and Gag protein ([Fig. 3](#fig3){ref-type="fig"}B), respectively. Results from Western blot analyses indicated that the gp120 protein was not detected in 293T cells transfected with plasmid pVAX1 ([Fig. 3](#fig3){ref-type="fig"}A, lane 1), but expressed in 293T cells transfected with plasmid pVAX1-gp120 ([Fig. 3](#fig3){ref-type="fig"}A, lane 2). The Gag protein of HIV-1 was not detected in *Salmonella* strain J341 ([Fig. 3](#fig3){ref-type="fig"}B, lane 1), but expressed in strains ST013 ([Fig. 3](#fig3){ref-type="fig"}B, lane 2) and ST014 ([Fig. 3](#fig3){ref-type="fig"}B, lane 3).Fig. 3Determination of viral protein expression in bacteria. Western blot assay for gp120 and Gag expression by Western blot analysis. (A). Determination of HIV-1 gp120 protein expression in 293T cells. 293T cells were transformed with plasmid pVAX1 (lane 1) and pVAX1-gp120 (lane 2). Proteins expressed in the mammalian cells were determined by Western blot analysis using antibody to HIV-1 gp120. (B) Determination of HIV-1 gag protein expression in recombinant *Salmonella* vaccine strains. Protein extracts were prepared from *Salmonella* strains, *S*. Typhi J341 (lane 1), ST013 (lane 2), and ST014 (lane 3), respectively. Proteins expressed in the bacteria were determined by western blot analysis using antibody to HIV-1 Gag protein.

3.3. Recombinant *Salmonella* vaccine strains induce high IgG antibody responses to gp120 protein of HIV-1 in immunized mice
----------------------------------------------------------------------------------------------------------------------------

To determine immune responses of recombinant *Salmonella* strains, BALB/c mice were randomly divided into five groups and vaccinated intranasally with 10^9^ CFU of the recombinant bacteria, respectively. Group 1 was immunized with strain ST011, group 2 with ST012, group 3 with ST013, group 4 with ST014, and group 5 was inoculated with PBS as a mock control. The booster immunization with 10^9^ CFU of recombinant bacteria was also given intranasally 15 days after first immunization.

Two weeks post-immunization, the gp120-specific IgG antibodies in the sera of immunized mice were determined by ELISA using purified HIV-1 Env protein as antigen. Results showed that high levels of gp120-specific IgG antibody responses in sera of mice vaccinated with ST012 or ST014 were detected compared to that of other three groups ([Fig. 4](#fig4){ref-type="fig"} ). The production of anti-Gag-specific antibodies in the serum of immunized mice were also determined by ELISA using p24 protein of HIV-1 as antigen. However, results showed that antibodies against p24 protein were not detected in sera after immunization with these recombinant *Salmonella* vaccine strains (data not shown).Fig. 4Detection of serum anti-HIV gp120 IgG production in mice immunized with recombinant *S*. Typhi vaccine strains by ELISA. Five groups of BALB/c mice were inoculated i.n. twice with 10^9^ CFU of recombinant *S*. Typhi vaccine strains ST011, ST012, ST013, ST014, and PBS, respectively. Two weeks post-immunization, sera were collected from vaccinated mice and analyzed by ELISA using purified HIV-1 Env protein as antigen for the detection of gp120-specific IgG antibodies responses. Horseradish peroxidase-conjugated goat anti-mouse IgG antibodies were used as the secondary antibodies. The optical densities were measured at 450 nm. Results represent the values (mean ± S.D.) for five mice per group from three different experiments.

3.4. Immunization with recombinant *Salmonella* vaccine strains stimulate high IgA antibody responses to gp120 protein of HIV-1 in the feces of vaccinated mice
---------------------------------------------------------------------------------------------------------------------------------------------------------------

To determine IgA antibody responses of vaccine strains, mice were vaccinated intranasally with 10^9^ CFU of the recombinant bacteria. The booster immunization with 10^9^ CFU of recombinant bacteria was given intranasally 15 days after first immunization. IgA antibody responses to gp120 protein from feces, vaginal secretions, and saliva of immunized mice were analyzed. Results from ELISA showed that high levels of gp120-specific IgA antibody activities were found only in feces of mice vaccinated with strains ST012 and ST014, but not in mice immunized with strains ST011, ST013, or PBS ([Fig. 5](#fig5){ref-type="fig"} ). We also noticed that gp120-specific IgA antibody activities were not detected in vaginal secretions or saliva of mice immunized with all the four vaccine strains (data not shown).Fig. 5Detection of intestine mucosal anti-HIV gp120 IgA production in mice immunized with recombinant *S*. Typhi vaccine strains by ELISA. Five groups of BALB/c mice were inoculated i.n. twice with 10^9^ CFU of recombinant *S*. Typhi vaccine strains ST011, ST012, ST013, ST014, and PBS, respectively. Two weeks post-immunization, fecal washes were collected from vaccinated mice and analyzed by ELISA using purified HIV-1 Env protein as antigen for the detection of gp120-specific IgA antibodies responses. Horseradish peroxidase-conjugated goat anti-mouse IgA antibodies were used as the secondary antibodies. The optical densities were measured at 450 nm. Results represent the values (mean ± S.D.) for five mice per group from three different experiments.

3.5. Immunization with recombinant *Salmonella* vaccine strains elicit HIV-1 gp120-specific cytotoxic T lymphocytes responses in vaccinated mice
------------------------------------------------------------------------------------------------------------------------------------------------

To analyze whether recombinant *Salmonella* vaccine strains could induce HIV-1 gp120-specific CTL responses, vaccinated mice were sacrificed 3 weeks post-immunization. Splenocytes were harvested and the CTL activities were measured by the Promega LDH release assay. Results showed that strong CTL responses were produced in mice immunized with the vaccine strains ST012 and ST014, but not detected in mice vaccinated with strains ST011 and ST013 or in the mock controls ([Fig. 6](#fig6){ref-type="fig"} ). When effecter to target ratio was 10:1, the gp120-specific CTL activity reached to 30%, while at 5:1 gp120-specific CTL activity reached above 15% in mice immunized with the vaccine strains ST012 and ST014.Fig. 6Determination of gp120-specific CTL activity in mice immunized with recombinant *S*. Typhi vaccine strains. Five groups of BALB/c mice were inoculated i.n. twice with 10^9^ CFU of recombinant *S*. Typhi vaccine strains ST011, ST012, ST013, ST014, and PBS, respectively. Three weeks post-immunization, mice were sacrificed and CTL activities were measured by the Promega LDH release assay. Mouse CT26 cells constitutively expressing HIV-1 gp120 were used as target cells and splenocytes from immunized mice were used as effector cells. Results represent the values (mean ± S.D.) for five mice per group from three different experiments.

3.6. Immunization with recombinant *Salmonella* vaccine strains elicit HIV-1 Gag-specific cytotoxic T lymphocytes responses in vaccinated mice
----------------------------------------------------------------------------------------------------------------------------------------------

HIV-1 Gag-specific CTL responses induced by recombinant *Salmonella* vaccine strains were also determined. Mice were sacrificed 3 weeks after immunization and CTL activities were measured by the Promega LDH release assay. Results showed that HIV-1 Gag-specific CTL responses were produced in mice vaccinated with strains ST013 and ST014 and that when effecter to target ratios were 10:1 and 5:1, Gag-specific CTL reached about 17% and 12%, respectively. However, HIV-1 Gag-specific CTL responses were not detected in mice immunized with strains ST011 and ST012 ([Fig. 7](#fig7){ref-type="fig"} ).Fig. 7Determination of Gag-specific CTL activity in mice immunized with recombinant *S*. Typhi vaccine strains. Five groups of BALB/c mice were inoculated i.n. twice with 10^9^ CFU of recombinant *S*. Typhi vaccine strains ST011, ST012, ST013, ST014, and PBS, respectively. Three weeks post-immunization, mice were sacrificed and CTL activities were measured by the Promega LDH release assay. Mouse CT26 cells constitutively expressing HIV-1 Gag were used as target cells and splenocytes from immunized mice were used as effector cells. Results represent the values (mean ± S.D.) for five mice per group from three different experiments.

4. Discussion
=============

HIV is transmitted by both venereal and parental routes. An ideal preventive vaccine must accordingly elicit both mucosal immunity that blocks sexual transmission of the virus and systemic immunity that eliminates virus transmitted hematogenously. Foreign antigen expression, delivery, and presentation mechanisms, as well as the innate biological and genetic traits of *Salmonella* vectors have been intensively investigated, all demonstrated that this living bacterium is a strong candidate for HIV vaccine development. Many studies have reported that attenuated derivatives of *S. enterica serovar* Typhi carrying HIV antigens could stimulate immune defenses in mammalians ([@bib3], [@bib5], [@bib8]).

Because HIV exists as cell-associated or cell-free particles in infected host, a fully effective vaccine should induce both cell mediated immune (CMI) responses that damage virus infected cells and neutralizing antibodies that target viral particles directly. CMI has proven to be critical for effective early control of replicating virus and clearance of intracellular pathogens. It is widely accepted that CMI against internal viral proteins of HIV is essential for eliminating infected cells because these viral proteins are structurally important and rarely generate mutant epitopes ([@bib19]). To induce durable and effective CMI responses, these viral proteins have to be endogenously synthesized to ensure their entering into proper antigen presentation pathway. A recombinant non-pathogenic *Leishmania* vaccine harboring an HIV-1 Gag expressing plasmid was reported to elicit cell mediated immunity ([@bib2]).

We generated a recombinant *Salmonella* vaccine strain ST014, in which HIV-1 *gag* gene was integrated into the bacterial chromosome and HIV-1 *gp120* gene was carried by a plasmid. Chromosomal integration generally increases the stability of foreign antigens and protects them from degradation by bacterial proteases ([@bib10], [@bib24]). The Gag antigen expression ([Fig. 3](#fig3){ref-type="fig"}B) and Gag-specific CTL activity (one of the most important CMI responses) ([Fig. 7](#fig7){ref-type="fig"}) were detected in mice immunized with this vaccine strain. Cellular immunity may prevent virus from attacking new susceptible cells, while antibodies play important roles in the first line of defense. As for the development of HIV vaccines, the viral envelop glycoprotein gp120 has always been the immunogen of choice ([@bib7]). Since the HIV gp120 is responsible for attachment to susceptible cells and is analogous to the highly immunogenic, its specific antibodies are considered to be crucial in the initial rounds of the campaign against HIV infection. In addition to CTL response, this recombinant vaccine strain could produce gp120 protein in mammalian cells ([Fig. 3](#fig3){ref-type="fig"}) and stimulate gp120-specific antibodies production in vaccinated mice ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}). There is evidence that multiple immune responses against multiple viral antigens (at least two) would establish superiority effects in the development of HIV vaccine ([@bib1]).

Although this recombinant *Salmonella* vaccine strain could not stimulate the production of Gag-specific antibodies in nasal immunized mice (date not shown), but could elicit a broad range of gp120-specific immune responses ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}). In addition, the gp120-specific CTL response was much higher than Gag-specific CTL response in the same experimental group ([Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}).

The gp120 glycoprotein complex enables the virus to attach to and fuse with the target cells to initiate the infectious cycle and is proved to be a highly immunogenic antigen. The Gag protein is an inner protein that helps assembly of viral nucleocapsid with less B cell epitopes and less immunogenic compared to gp120. Unlike the gp120 protein expressed from the eukaryotic plasmid, the level of Gag protein expressed from *S*. Typhi chromosome is relatively low when introduced into mammalian host. Thus, less anti-Gag antibodies (IgG or IgA) were produced in our study. This result was consistent with other report, which also showed that Gag-specific antibodies were hardly detected ([@bib2]). However, since the sequences of Gag are more conservative than that of gp120, the cellular reaction against this important structural protein would be more crucial in the long-term host immune response against HIV.

We are currently in the process of addressing the above problem by utilization of appropriate and stronger promoters in *Salmonella* chromosome in order to optimize the chromosomal gene expression and antigen production to enhance the immune responses to the Gag antigen.

Our previous work has compared the efficiencies of nasal or oral routs of immunization in mice inoculated with recombinant *Salmonella* living vaccines and demonstrated that intranasal vaccination was more efficient than orogastric immunization ([@bib13]). Thus, we chose intranasal immunization instead of orogastric immunization for the induction of mucosal and systemic anti-HIV immune responses in this study. It is generally agreed that orogastric route for live bacterial vectors may be inefficient because the gastrointestinal tract contains commensal bacteria, other microorganisms, stomach acid, proteolytic enzymes, together with food might interfere with vaccine uptake and suppress immune responses ([@bib6], [@bib17]). In contrast, the nasal cavity surface provides a smooth environment that is replete with antigen-reactive lymphoid elements, including T cells, B cells, and a large number of cellular components involved in the induction of immune responses. Intranasal immunization could lead to the induction of distant mucosal immune responses ([@bib14], [@bib26]). The genital, rectal, and oral sites are considered to be most important for induction of strong mucosal immune responses to block the invasion of HIV through sexual intercourse.

gp120-specific IgA mucosal antibodies were detected in fecal washes (but not in saliva or vaginal secretions), which suggests that rectal immune response was elicited by the vaccine candidate. It has been reported that HIV infection rates were higher for homosexual injection drug users (34%) than for bisexuals (16%) or heterosexuals (13%) ([@bib25]). Thus, we considered that rectal secreted S-IgA was important in the development of anti-HIV vaccine, since rectal sex is quite common in homosexual population.

In this study, we obtained genes from plasmid pNL4-3 containing the full-length HIV-1 proviral sequence, which is CXCR4 specific, while primary infection is sustained almost invariably by CCR5-dependent viruses. Thus, this represents a potential limitation of the possibility of translating the results to clinics. Experiments with an HIV-1 clone specific to CCR5 would be more suitable. However, the main purpose of this study was to test this vaccination strategy for the induction of broadly immune responses to multiple HIV antigens. On the basis of this platform we constructed, it is quite convenient to test antigens derived from other viral strains and evaluate the immune responses they might induce.

5. Conclusions
==============

We generated a novel recombinant *S*. *enterica serovar* Typhi strain that can present the gag and gp120 dual antigens of HIV-1 to the host. Initial experimental results demonstrated that this *Salmonella* vaccine strain could elicit multiple immune responses, including humoral, cellular, and mucosal responses, in mice immunized intranasally with this vaccine strain. Compared to the common bimodal vaccine approach in which CTL and antibody responses are induced by the combination of a live recombinant vector (or a plasmid DNA) and a subunit immunogen, this recombinant *Salmonella* strain provides a relatively easier approach of single recombinant microbial vaccination. In addition, this vaccine strain can immunize via mucosal surfaces without the use of syringe injection, which would make this vaccination more acceptable from the patient\'s perspective. Thus, it would provide a new approach to the prevention of HIV/AIDS.
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